Skip to main content

Remote Job Finders (RJF)

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by quality problems at an ex-Catalent facility in Indiana. Novo Nordisk, meanwhile, has been tight-lipped about whether its own FDA applications have been affected.
Biotechs Secure Alternative Fill/Finish Capacity Amid Scrutiny of Novo Site
Scroll to top